Company: AZN
Filing Date: 2025-07-16
Form Type: 6-K
Source: 0001654954-25-008111
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-07-16
Form: 6-K
Chunk 4
---
 Amyloidosis for Cardiologists; Awareness, Diagnosis, and Future Prospects. JACC: CardioOncology. 2022;4(4): 427- 441.

5. Kumar N, et al. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis . 2022;17(278).

6. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES). NCT Identifier: NCT04512235. Available here . Accessed June 2025.

7. ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES). NCT Identifier: NCT04504825. Available here . Accessed June 2025.

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date :16 July 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |